Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11257659 | 0.86 | GRIK1 (0.31) | GRIK1GRIK2 | |
| SCHEMBL3092130 | 0.80 | GRIK1 (0.48) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8847435 | 0.76 | GRIK1 (0.38) | GRIK1GRIK2 | |
| SCHEMBL8847417 | 0.76 | GRIK1 (0.38) | GRIK1GRIK2 | |
| SCHEMBL435187 | 0.75 | GRIK1 (0.35) | GRIK1GRIK2 | |
| SCHEMBL8847379 | 0.72 | GRIK1 (0.48) | GRIK1GRIK2 | |
| SCHEMBL8847250 | 0.72 | GRIK1 (0.36) | GRIK1GRIK2 | |
| SCHEMBL8847232 | 0.72 | GRIK1 (0.36) | GRIK1GRIK2 | |
| SCHEMBL19105392 | 0.71 | TSHR (0.31) | — | |
| SCHEMBL17159665 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE37670-E1 | Antiproliferative and neurotrophic molecules | AMERICAN BIOGENETICS INC. | 2002-04-23 | — | — | US | claimed |
| US-20020013367-A1 | Antiproliferative and neurotrophic molecules | NAU HEINZ (DE) | 2002-01-31 | — | — | US | claimed |
| US-6300373-B1 | CONTACTING NEURONAL CELLS WITH A NEUROTROPHIC AMOUNT CARBOXYLIC ACID DERIVATIVE FOR PROVIDING NEUROTROPHIC ACTIVITY | AMERICAN BIOGENETIC SCIENCES, INC. | 2001-10-09 | — | — | US | claimed |
| EP-0778820-B1 | NEUROTROPHIC AND ANTIPROLIFERATIVE COMPOUNDS | AMERICAN BIOGENETIC SCIENCES (US) | 2001-05-02 | — | — | EP | claimed |
| EP-0778820-A1 | NEUROTROPHIC AND ANTIPROLIFERATIVE COMPOUNDS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1997-06-18 | — | — | EP | claimed |
| WO-1996006821-A1 | NEUROTROPHIC AND ANTIPROLIFERATIVE COMPOUNDS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1996-03-07 | — | — | WO | claimed |
| US-RE37670-E1 | Antiproliferative and neurotrophic molecules | AMERICAN BIOGENETICS INC. | 2002-04-23 | — | — | US | disclosed |
| US-20020013367-A1 | Antiproliferative and neurotrophic molecules | NAU HEINZ (DE) | 2002-01-31 | — | — | US | disclosed |
| US-6300373-B1 | CONTACTING NEURONAL CELLS WITH A NEUROTROPHIC AMOUNT CARBOXYLIC ACID DERIVATIVE FOR PROVIDING NEUROTROPHIC ACTIVITY | AMERICAN BIOGENETIC SCIENCES, INC. | 2001-10-09 | — | — | US | disclosed |
| US-6274624-B1 | COMPOUNDS SUCH AS 2-N-PENTYL-4-PENTYNOIC ACID AS ANTIMITOTIC AGENTS | AMERICAN BIOGENETIC SCIENCES INC. | 2001-08-14 | — | — | US | disclosed |
| EP-0778820-B1 | NEUROTROPHIC AND ANTIPROLIFERATIVE COMPOUNDS | AMERICAN BIOGENETIC SCIENCES (US) | 2001-05-02 | — | — | EP | disclosed |
| US-5672746-A | UNSATURATED ALKYL CARBOXYLIC ACIDS(AND THEIR SALTS) FOR TREATMENT OR PREVENTION OF NERVOUS SYSTEM DISORDERS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0778820-A1 | NEUROTROPHIC AND ANTIPROLIFERATIVE COMPOUNDS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1997-06-18 | — | — | EP | disclosed |
| WO-1996006821-A1 | NEUROTROPHIC AND ANTIPROLIFERATIVE COMPOUNDS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013367-A1 | Antiproliferative and neurotrophic molecules | BDNF, NGF, NTRK2 | GRIK1 305/4885GRIK2 229/4885TGFBR1 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.